Avania, a medical technology contract research organisation (CRO), has acquired MAXIS, a prominent medical technology development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management.
wan wei Shutterstock
1365692276
Merging, two merchants push the red squares and other squares together
MAXIS has offices in San Jose and Frankfurt with additional operational staff across the regions. With MAXIS, the combined organisation offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs).
Sapna Hornyak, president and CEO of Avania, said: “This acquisition strengthens our position as the leading medtech focused CRO, advancing innovative medical technologies from ideation to commercialisation, providing a range of highly customisable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emerging OEMs. The addition of MAXIS furthers our strategy and will provide us with enhanced capabilities across a broader customer base as we continue to innovate and grow.”
MAXIS clients will benefit from Avania’s extended international footprint, gaining access to the company’s extensive network in the U.S., EU, and Australia. Additionally, Avania brings enhanced services to the combined companies — including biostatistics, data analytics, and medical writing.
Kathleen Marshall, president of MAXIS Medical, said: “MAXIS’ long-standing commitment to emerging technology companies will be greatly enhanced with Avania’s sophisticated infrastructure and extensive resources. Avania’s understanding of our strategic value in the continuum of medical technology development was compelling and decisive, and we are delighted to be able to continue our mission with the Avania team.”
